Results 241 to 250 of about 10,497,872 (316)
MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) [PDF]
DEVELOPMENT GROUP MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) MOH MALAYSIA
doaj
Sengstaken-Blakemore Tube Placement: A Simulation-Based Training Program for a High-Acuity, Low-Frequency Procedure. [PDF]
Wilson C +7 more
europepmc +1 more source
ABSTRACT Objective To explore how cerebral hypoxia and Normal‐Appearing White Matter (NAWM) integrity affect MS lesion burden and clinical course. Methods Seventy‐nine MS patients, including 13 clinically isolated syndrome (CIS) patients and 66 relapsing–remitting multiple sclerosis (RRMS) patients, and 44 healthy controls (HCs) were recruited from ...
Xinli Wang +8 more
wiley +1 more source
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane +43 more
wiley +1 more source
Distal Third Minimally Displaced Stress Fracture of Fibula in a Military Recruit: A Case Report and Review of Literature. [PDF]
Poudel A, Rai B, Devkota D, Dhungana V.
europepmc +1 more source
ABSTRACT Objective This analysis evaluates the effect of successful reperfusion on functional outcomes after MT, stratified by admission National Institutes of Health Stroke Scale (NIHSS) and Alberta Stroke Program Early CT Score (ASPECTS) as surrogates for clinical‐core mismatch, using multicenter registry data.
Felix Schlicht +53 more
wiley +1 more source
Editorial: Innovation, technology and sustainability in sport management and education. [PDF]
Van Den Berg L +4 more
europepmc +1 more source
Clinical Validation of Plasma p‐217tau in Neurological Diseases
ABSTRACT Objective Plasma p‐217tau is a minimally invasive but specific biomarker for diagnosing Alzheimer's disease (AD). However, its disease specificity remains to be clinically evaluated. We validated the reliability of the p‐217tau biomarker in 12 other neurological diseases.
Takeshi Kawarabayashi +13 more
wiley +1 more source
Complementary views: addressing blind spots in the direct versus video laryngoscopy debate. [PDF]
Flynn SG +6 more
europepmc +1 more source

